Despite this variation, a more recent meta‐analysis of all these trials confirmed the beneficial actions of GLP‐1 mimetics through a 13% relative risk reduction in cardiovascular disease mortality, 12% risk reduction in all‐cause mortality and 10% relative risk reduction in cardiovascular death, non‐fatal myocardial infarction and non‐fatal stroke (Bethel et al., 2018). This evidence concerns the gene GLP1R and myocardial infarction.